Recent Updates
Recently added Catalysts
MANE Positive Sentiment

Veradermics to Present at Upcoming September Investor Conferences

Thursday, September 3, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Veradermics, a late-stage biopharmaceutical company, has announced its participation in key investor conferences in September 2026. The company, which specializes in therapeutics for pattern hair loss, will present at the Wells Fargo 21st Annual Healthcare Conference and the Citi's 2026 Biopharma Back to School Conference. This engagement highlights Veradermics' commitment to connecting with the investment community.

Market Sentiment Analysis

POSITIVE FACTORS

  • Veradermics is actively engaging with investors.
  • Participation in multiple prestigious conferences.
  • Focus on innovative therapeutics for hair loss.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~169 mo
Minimal dilution risk
Lead asset
VDPHL01
Phase 3 · Androgenetic Alopecia

Full Press Release Details

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will participate in the following upcoming investor conferences in September: Wells Fargo 21st Annual Healthcare Conference Investor Meetings: Tuesday, September 8, 2026 in Boston, MA Citi's 2026 Biopharma Back to School Conference Presentation: Wednesd

Frequently Asked Questions

What is Veradermics focused on?

Veradermics develops innovative therapeutics for pattern hair loss.

When will Veradermics present at investor conferences?

Veradermics will present at conferences in September 2026.

Which conferences will Veradermics attend?

They will participate in the Wells Fargo and Citi's Biopharma conferences.

Where is the Wells Fargo conference held?

The Wells Fargo conference will take place in Boston, MA.

ShareAdd on Google
Tags: MANE Viatris Investor Conferences Healthcare Veradermics investor conferences biopharmaceuticals hair loss
Last updated: Sep 3, 2026

Biotech snapshot

Cash runway
$820M liquidity · $5M/mo burn
~169 mo
Minimal dilution risk
Lead asset
VDPHL01Phase 3
Androgenetic Alopecia →